Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea
Primary Purpose
Irritable Bowel Syndrome
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Herbal extract granule and probiotics
Herbal extract granule and placebo probiotics
Placebo herbal extract granule and probiotics
Placebo herbal extract granule and placebo probiotics
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Irritable bowel syndrome, Herbal medicine, Probiotics
Eligibility Criteria
Inclusion Criteria:
- Age of 18 - 75, with a elementary-school diploma or higher, must be literate
- One who meet Rome Ⅲ IBS-D criteria
- One who agree on not taking other therapies during experimental period
- During the past 5 yrs, no history of organic lesion proven by colonoscopy
- One who agree on consent form
Exclusion Criteria:
- Patients who have abdominal operation in the past(exception: appendectomy, caesarean section, tubal ligation, laparoscopic cholecystectomy, hysterectomy and abdominal wall hernia repair)
- No history of non-functional bowel disease(cholangitis, pancreatitis, enteritis, ulcer, bleeding, cancer, etc.)
- Before participation clinical trial, one who took over-the-count medication affecting GI motility
- One who takes antibiotics during run-in period (2 wks)
- One who takes probiotics within 2 wks before experiment
- Pregnant woman
- One who disagree on the consent form
Sites / Locations
- Kyung Hee University Hospital at Gangdong
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Placebo Comparator
Placebo Comparator
Placebo Comparator
Arm Label
GJS/Duolac7S
GJS-P/Duolac7S
GJS/Duolac7S-P
GJS-P/Duolac7S-P
Arm Description
GJS: Real herbal extract granule/Duolac7S: Real probiotics
GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
Outcomes
Primary Outcome Measures
Adequate relief (AR) of IBS pain & discomfort
As the participants answer the question "in the past seven days have you had adequate relief of your irritable bowel syndrome pain and discomfort?" in the form of "Yes" or "No", the effect can be assessed.
Proportion of responders
The proportion of responders who answer "Yes" to more than half of AR questions in each period (>50%)
Secondary Outcome Measures
Daily assessment of bowel function scores
The patients should write diaries of stool's frequency, consistency and ease of passage
Frequency (number of defecation in a day)
Consistency (judged by Bristol scale)
Ease of passage
Daily assessment of severity of individual symptoms related to defecation
Abdominal pain, abdominal discomfort, bloating, flatulence, urgency, mucus in stool and overall symptom would be evaluated through visual analog scale (100mm)
Changes on population of intestinal microbes
To investigate the changes of intestinal microbes before and after experiment, feces should be collected.
The feces will be analyzed by the method of DGGE (denaturing gradient gel electrophoresis - PCR of DNA).
Intestinal permeability test
In order to evaluate intesinal permeability, the urine should be collected after orally administration of lactulose and mannitol.
Full Information
NCT ID
NCT01342718
First Posted
April 25, 2011
Last Updated
June 1, 2012
Sponsor
Kyunghee University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01342718
Brief Title
Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea
Official Title
Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kyunghee University Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aims of this study are to investigate the effect of famous herbal formula extract and probiotics on irritable bowel syndrome with diarrhea, and to determine whether these two experimental items affect intestinal permeability and the composition of intestinal microbiota.
Detailed Description
Irritable bowel syndrome (IBS), a common chronic gastrointestinal disorder characterized by abdominal pain and alteration of bowel habits in the absence of structural abnormality, has a prevalence of approximately 15% in western populations1,2. Patients with IBS can be classified by their predominant bowel habits: diarrhea-predominant IBS (D-IBS), constipation-predominant IBS, or IBS with alternating bowel movements3. Although smooth-muscle relaxants, bulking agents, and anti-diarrheal agents are commonly used as conventional IBS treatments, many IBS patients turn to alternative treatments because of the lack of therapeutic advantages of these treatments4. Therefore, the development of a new therapy is necessary for IBS patients.
Gwakhyangjeonggisan (GJS; Kkako-shoki-san in Kampo Medicine; Huoxiang-zhengqi-san in Traditional Chinese Medicine), which was recorded originally in the famous ancient herbal formula literature "Formularies of the Bureau of people's Welfare Pharmacies", consists of 13 common crude herbs. GJS contains the chemical ingredients naringin, hesperidin, thymol, honokiol and magnolol5. GJS has been shown to protect intestinal barrier function6, contract the colonic muscle7, and regulate infectious diarrhea8 in vivo. In traditional Korean medicine, this herbal formula has long been used for relieving abdominal pain, diarrhea, and vomiting as an over-the-counter or prescribed medicine9-11. However, there have been no clinical trials to investigate the efficacy of GJS in IBS.
Probiotics are defined as viable microorganisms, which confer potential health benefits on the host when taken in proper amounts12. They are easily available, do not require a prescription, and are administered extensively for the relief of abdominal symptoms13. According to a recent systematic review and meta-analysis study, probiotics caused a modest improvement in the overall IBS symptoms14. The rationale for using probiotics for IBS is based on the assumption that they modify the composition of the intestinal microflora15 and regulate intestinal permeability by modulating the epithelial tight junctions16. Duolac7S (DUO), a probiotic mixture, contains 7 bacterial species including Bifidobacterium, Lactobacillus, and Streptococcus. Each of these bacterial species is reportedly beneficial for IBS17. DUO has been approved by the Korean Food and Drug Administration for restoring the ecological balance of intestinal microflora and improving intestinal symptoms18. Although DUO has been widely used as an over-the-counter product for IBS-related symptoms, no clinical trials have investigated the efficacy of DUO on IBS.
Recently, several herbal formulas and probiotics have been simultaneously administered to IBS patients for relieving abdominal symptoms19. In addition to lack of clinical evidence for the use of GJS or DUO, the efficacy of their combined treatment for IBS has not been elucidated. Thus, there is a need to evaluate the safety and efficacy of administration of GJS, DUO, or a combination therapy as a frequently used treatment for IBS. In the current trial, we identified the safety and efficacy of GJS, DUO, or a combination therapy on D-IBS by evaluating IBS symptoms and quality of life. To investigate their mechanisms in humans, intestinal permeability and composition of intestinal microbiota were assessed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
Irritable bowel syndrome, Herbal medicine, Probiotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GJS/Duolac7S
Arm Type
Experimental
Arm Description
GJS: Real herbal extract granule/Duolac7S: Real probiotics
Arm Title
GJS-P/Duolac7S
Arm Type
Placebo Comparator
Arm Description
GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
Arm Title
GJS/Duolac7S-P
Arm Type
Placebo Comparator
Arm Description
GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
Arm Title
GJS-P/Duolac7S-P
Arm Type
Placebo Comparator
Arm Description
GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
Intervention Type
Dietary Supplement
Intervention Name(s)
Herbal extract granule and probiotics
Other Intervention Name(s)
Gwakhyangjeonggisan granule and Duolac7S
Intervention Description
The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)
Intervention Type
Dietary Supplement
Intervention Name(s)
Herbal extract granule and placebo probiotics
Other Intervention Name(s)
Gwakhyangjeonggisan granule and placebo Duolac7S
Intervention Description
The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo herbal extract granule and probiotics
Other Intervention Name(s)
Placebo Gwakhyangjeonggisan granule and Duolac7S
Intervention Description
The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo herbal extract granule and placebo probiotics
Other Intervention Name(s)
Placebo Gwakhyangjeonggisan granule and placebo Duolac7S
Intervention Description
The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Primary Outcome Measure Information:
Title
Adequate relief (AR) of IBS pain & discomfort
Description
As the participants answer the question "in the past seven days have you had adequate relief of your irritable bowel syndrome pain and discomfort?" in the form of "Yes" or "No", the effect can be assessed.
Time Frame
Weekly (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])
Title
Proportion of responders
Description
The proportion of responders who answer "Yes" to more than half of AR questions in each period (>50%)
Time Frame
Once in each period (run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])
Secondary Outcome Measure Information:
Title
Daily assessment of bowel function scores
Description
The patients should write diaries of stool's frequency, consistency and ease of passage
Frequency (number of defecation in a day)
Consistency (judged by Bristol scale)
Ease of passage
Time Frame
Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])
Title
Daily assessment of severity of individual symptoms related to defecation
Description
Abdominal pain, abdominal discomfort, bloating, flatulence, urgency, mucus in stool and overall symptom would be evaluated through visual analog scale (100mm)
Time Frame
Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])
Title
Changes on population of intestinal microbes
Description
To investigate the changes of intestinal microbes before and after experiment, feces should be collected.
The feces will be analyzed by the method of DGGE (denaturing gradient gel electrophoresis - PCR of DNA).
Time Frame
Two times in administration period (0 and 8 wks)
Title
Intestinal permeability test
Description
In order to evaluate intesinal permeability, the urine should be collected after orally administration of lactulose and mannitol.
Time Frame
Two times in administration period (0 and 8 wks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age of 18 - 75, with a elementary-school diploma or higher, must be literate
One who meet Rome Ⅲ IBS-D criteria
One who agree on not taking other therapies during experimental period
During the past 5 yrs, no history of organic lesion proven by colonoscopy
One who agree on consent form
Exclusion Criteria:
Patients who have abdominal operation in the past(exception: appendectomy, caesarean section, tubal ligation, laparoscopic cholecystectomy, hysterectomy and abdominal wall hernia repair)
No history of non-functional bowel disease(cholangitis, pancreatitis, enteritis, ulcer, bleeding, cancer, etc.)
Before participation clinical trial, one who took over-the-count medication affecting GI motility
One who takes antibiotics during run-in period (2 wks)
One who takes probiotics within 2 wks before experiment
Pregnant woman
One who disagree on the consent form
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jae-Woo Park, KMD, PhD
Organizational Affiliation
Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyung Hee University Hospital at Gangdong
City
Seoul
State/Province
Gangdong-gu
ZIP/Postal Code
130-701
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
21978382
Citation
Ko SJ, Ryu B, Kim J, Hong BG, Yeo I, Lee BJ, Lee JM, Park JW. Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial. Trials. 2011 Oct 6;12:219. doi: 10.1186/1745-6215-12-219.
Results Reference
derived
Links:
URL
http://www.khnmc.or.kr/
Description
This is the URL of the site in which the clinical trial will be conducted.
Learn more about this trial
Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea
We'll reach out to this number within 24 hrs